NEW YORK, May 23, 2018 /PRNewswire/ --
Guillain–Barré Syndrome Market – OverviewThis report on the global Guillain–Barré syndrome market studies the current as well as future prospects of the market globally.Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain–Barré syndrome as well as new entrants planning to enter the market.Read the full report: https://www.reportlinker.com/p05400955 This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain–Barré syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.Based on therapeutics, the Guillain–Barré syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain–Barré syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain–Barré syndrome and available treatment options for Guillain–Barré syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain–Barré syndrome market and that could also influence the market in the near future.Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies.The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain–Barré syndrome market.Geographically, the global Guillain–Barré syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.The report also provides the market size and forecast for major countries in the respective region.A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section.This section of the report also provides market attractiveness analysis, Porter's five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain–Barré syndrome market.Key players operating in the global Guillain–Barré syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.The global Guillain–Barré syndrome market has been segmented as follows:Global Guillain–Barré Syndrome Market, by TherapeuticsIntravenous ImmunoglobulinPlasma ExchangeOthers (Analgesics, Anticonvulsants, LMWH, etc.)Global Guillain–Barré Syndrome Market, by Route of AdministrationOralParenteralGlobal Guillain–Barré Syndrome Market, by Distribution ChannelHospital PharmaciesRetail PharmaciesOthers (Home Care, Clinics, etc.)Global Guillain–Barré Syndrome Market, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceItalySpainU.K.Rest of EuropeAsia PacificASEANIndiaJapanChinaRest of Asia PacificRest of WorldRead the full report: https://www.reportlinker.com/p05400955 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
Guillain–Barré Syndrome Market – OverviewThis report on the global Guillain–Barré syndrome market studies the current as well as future prospects of the market globally.Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain–Barré syndrome as well as new entrants planning to enter the market.Read the full report: https://www.reportlinker.com/p05400955 This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain–Barré syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.Based on therapeutics, the Guillain–Barré syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain–Barré syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain–Barré syndrome and available treatment options for Guillain–Barré syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain–Barré syndrome market and that could also influence the market in the near future.Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies.The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain–Barré syndrome market.Geographically, the global Guillain–Barré syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.The report also provides the market size and forecast for major countries in the respective region.A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section.This section of the report also provides market attractiveness analysis, Porter's five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain–Barré syndrome market.Key players operating in the global Guillain–Barré syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.The global Guillain–Barré syndrome market has been segmented as follows:Global Guillain–Barré Syndrome Market, by TherapeuticsIntravenous ImmunoglobulinPlasma ExchangeOthers (Analgesics, Anticonvulsants, LMWH, etc.)Global Guillain–Barré Syndrome Market, by Route of AdministrationOralParenteralGlobal Guillain–Barré Syndrome Market, by Distribution ChannelHospital PharmaciesRetail PharmaciesOthers (Home Care, Clinics, etc.)Global Guillain–Barré Syndrome Market, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceItalySpainU.K.Rest of EuropeAsia PacificASEANIndiaJapanChinaRest of Asia PacificRest of WorldRead the full report: https://www.reportlinker.com/p05400955 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/guillain-barre-syndrome-market---global-industry-analysis-size-share-growth-trends-and-forecast-2017---2025-300653914.html
SOURCE Reportlinker
